Adverse motor effects induced by antiepileptic drugs

Epileptic Disorders

Volumn 6, Issue 3, 2004, Pages 153-168

  Zaccara, G ^a   Cincotta, M ^a   Borgheresi, A ^a   Balestrieri, F ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Adverse effects; Antiepileptic drugs; Ataxia; Diplopia; Dyskinesias; Movement disorders; Myoclonus; Parkinsonism tremor

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LITHIUM; LOSIGAMONE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AKATHISIA; ARTICLE; ATAXIA; ATHETOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHOREA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DYSKINESIA; DYSTONIA; GAZE PARALYSIS; HUMAN; MOTOR DYSFUNCTION; MYOCLONUS; NYSTAGMUS; OCULOGYRIC CRISIS; OPHTHALMOPLEGIA; OSCILLOPSIA; PARKINSONISM; PRIORITY JOURNAL; SOMNOLENCE; TARDIVE DYSKINESIA; TIC; TREMOR; VERTIGO;

ANTICONVULSANTS; CLINICAL TRIALS; DIZZINESS; DYSKINESIA, DRUG-INDUCED; HUMANS; MYOCLONUS; OCULOMOTOR NERVE DISEASES; PARKINSON DISEASE, SECONDARY; POSTURE; RANDOMIZED CONTROLLED TRIALS; TICS;

EID: 8344224621     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (219)

1. Park BK, Pirmohamed K, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95.
2. Wason S, Savitt D. Acute Valproic acid toxicity at therapeutic concentrations. Clin Pediatr 1985; 24: 466-7.
3. Zaccara G, Campostrini R, Paganini M, Moroni F, et al. Acute changes of blood ammonia concentrations may help to predict valproic acid short-term adverse effects. Neurology 1984; 34: 1519-21.
4. Zaccara G, Paganini M, Campostrini R, Moroni F, et al. Effect of associated antiepileptic treatment on valproate-induced hyperammonaemia. Therap Drug Monit 1985; 7: 185-90.
5. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15: 378-93.
6. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000; 41 (Suppl 2): S42-S52.
7. Wong ICK, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000; 23: 35-56.
8. Cochrane HC, Marson AG, Baker GA, Chadwick DW. Neuropsychological outcomes in randomised controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 1998; 39: 1088-97.
9. Meador KJ. Current discoveries on the cognitive effects of antiepileptic drugs. Pharmacotherapy 2000; 20: 185S-190S.
10. Baker GA, Marson AG. Cognitive and behavioural assessments in clinical trials: what type of measure? Epilepsy Res 2001; 45: 163-7.
11. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. Drugs 2002; 62: 593-604.
12. Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002; 58 (Suppl. 5): S21-6.
13. Collaborative Group for epidemiology of epilepsy. Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Epilepsia 1986; 27: 323-30.
14. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
15. th Edition. New York: Raven Press, 2002: 301-8.
16. Sachdeo RC, Edwards K, Hasegawa H et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy. Neurology 1999; 52 (Suppl. 2): A391.
17. Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 1964; 11: 642-8.
18. th Edition. Philadelphia: Lippincott Williams, Wilkins, 2002: 605-10.
19. Riva R, Albani F, Ambrosetto G, Contin M et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984; 25: 476-81.
20. Riva R, Contin M, Albani F, Perucca E, et al. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its free 10,11-epoxide metabolite. Therap Drug Monit 1985; 7: 277-82.
21. Specht U, May TW, Rohde M, Wagner V, Schmidt RC, Schutz M, and Wolf P. Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy. Arch Neurol 1997; 54: 427-31.
22. Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology 1988; 38: 755-9.
23. Seymour JF. Carbamazepine overdose. Features of 33 cases. Drug Saf 1993; 8: 81-8.
24. th Edition. Philadelphia: Lippincott Williams,Wilkins, 2002: 489-95.
25. th Edition. Philadelphia: Lippincott Williams, Wilkins, 2002: 837-51.
26. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalised tonic-clonic seizures. N Engl J Med 1985; 313: 145-51.
27. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalised tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-71.
28. Richens A, Davidson DLW, Cartlidge NEF, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682-7.
29. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, Reynolds EH. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
30. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in pediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108.
31. De Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BJR, Johnson AL, Reynolds EH. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13.
32. Willmore LJ, Shu V, Wallin B. Efficacy and safety of add-on Divalproex sodium in the treatment of complex partial seizures. Neurology 1996; 46: 49-53.
33. Hoppener RJ, Kuyer A, Meijer JWA, Hulsman J. Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980; 21: 341-50.
34. Wildin JD, Pleuvry BJ, Mawer GE. Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of liquid suspension to naïve subjects. Br J Clin Pharmacol 1993; 35: 14-19.
35. Canger R, Altamura AC, Belvedere O, et al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 1990; 82: 9-13.
36. Lesser RP, Pippenger CE, Luders H, Dinner DS. High dose monotherapy as treatment in intractable seizures. Neurology 1984; 34: 707-11.
37. Delker A, Wilhelm H, Timmann D, Diener HC. Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Euro Neuropsychopharmacol 1997; 7: 213-8.
38. Ghatak NR, Santoso RA, McKinney WM. Cerebellar degeneration following long term phenytoin therapy. Neurology 1976; 26: 818-20.
39. Munoz-Garcia D, Delser T, Bermejo F, et al. Truncal ataxia in chronic anticonvulsant treatment: association with drug-induced folate deficiency. J Neurol Sci 1982; 55: 305-11.
40. Botez MI, Gravel J, Attig E, Velina JL. Reversible chronic cerebellar ataxia after Phenytoin intoxication. Neurology 1985; 35: 1152-7.
41. Haberland C. Cerebellar degeneration with clinical manifestation in chronic epileptic patients. Psychiatr Neurol 1962; 143: 29-44.
42. Riley CG. Chronic hydantoin intoxication: case report. NZ Med J 1972; 76: 425-8.
43. Selhorst JB, Kaufman B, Horwitz SJ. Diphenylhydantoin-induced cerebellar degeneration. Arch Neurol 1972; 27: 453-55.
44. Kuruvilla T, Bharucha NE. Cerebellar atrophy after acute phenytoin intoxication. Epilepsia 1997; 38: 500-2.
45. Dam M. The density and ultrastructure of the Purkinje cells following diphenylhydantoin treatment in animals and man. Copenhagen: Bogtrykkeriet Forum, 1972.
46. Julien RM, Laxer KD. Cerebellar responses to penicillin-induced cerebral cortical epileptiform discharge. Electroenchephalogr Clin Neurophysiol 1974; 37: 123-32.
47. Rapport RL, Shaw CM. Phenytoin-related cerebellar degeneration without seizures. Ann Neurol 1977; 2: 437-9.
48. Tan EK, Chan LL, Auchus AP. Phenytoin cerebellopathy without epilepsy. Acta Neurol Scand 2001; 104 (1): 61-2.
49. Awada A, Amene P, al Jumah M, al Beladi K. Residual cerebellar ataxia following acute phenytoin intoxication. Rev Neurol 1999; 155: 306-8.
50. Alioglu Z, Sari A, Velioglu SK, Ozmenoglu M. Cerebellar atrophy following acute Phenytoin intoxication. J Neuroradiol 2000; 27: 52-5.
51. th Edition Philadelphia, Lippincott Williams,Wilkins, 2002: 565-80.
52. Young GB, Oppenheimer SR, Gordon BA, Wells GA, Assis LPA, Kreeft JH, et al. Ataxia in institutionalised patients with epilepsy. Can J Neurol Sci 1994; 21: 252-8.
53. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9.
54. Reunanen M, Dam M, Yuen AWC. A randomised open multicentre trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed epilepsy. Epilep Res 1996; 23: 149-5.
55. Brodie MJ, Overstall PW, Giorgi L. Multicentre, doubleblind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilep Res 1999; 37: 81-7.
56. Steiner TJ, Dellaportas CI, Findley LJ, Gros M, Gibberd FB, Perkin GD, Park DM, Abbot R. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601-6.
57. Bill PA, Vigonius U, Pohlman H, Gurreiro CAM, Kochen S, Saffer D, Moore A. A double-blind controlled clinica trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilep Res 1997; 27: 195-204.
58. Gurreiro CAM, Vigonius U, Pohlman H, de Manreza G, Fejerman N, Antoniuk SA, Moore A. A controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescent with epilepsy. Epilep Res 1997; 27: 205-13.
59. Christie W, Kramer G, Vigonius U, Pohlman H, Steinhoff BJ, Brodie M, Moore A. A double-blind controlled clinica trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilep Res 1997; 26: 451-60.
60. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilep Res 1989; 3: 70-6.
61. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13-9.
62. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995; 52: 989-96.
63. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, Pierce MW. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282-8.
64. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
65. Mullens EL. Clinical experience with lamotrigine monotherapy in adults with newly diagnosed epilepsy. A review of published randomised clinia trials. Clin Drug Invest 1998; 16: 125-33.
66. Marson AG, Kadir ZA, Hutton JL, Chadwick. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
67. Marson AG, Hutton JL, JP Leach, Castillo S, Schmidt D, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilep Res 2002; 46: 259-70.
68. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilep Res 2001; 47: 17-25.
69. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. The Cochrane Library, 2001; 1.
70. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. The Cochrane Library, 2001; 1.
71. th Edition, Philadelphia, Lippincott Williams, Wilkins, 2002: 466-9.
72. Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-7.
73. Kapteyn TS, de Wit G. Posturography as an auxiliary in vestibular investigation. Acta Otolaryngol 1972; 73 (2): 104-11.
74. Patat A and Foulhoux P. Effect of postural sway of various benzodiazepine tranqullizers. Br J clin Pharm 1985; 20: 9-16.
75. Noachtar S, von Maydell B, Fuhry L, Buttner U. Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side effects in healthy volunteers. Epilep Res 1998; 31: 47-57.
76. Steinhoff BJ, Kunkel M, Freudenthaler N, Paulus W. Influence of standard and new antiepileptic drugs on posture in healthy volunteers: a double-blind, placebo-controlled, single dose study. Epilepsia 1996; 37 (Suppl. 4): S84-5.
77. Leigh RJ, Zee DS. The neurology of eye movements. Oxford, Oxford University press, 1999.
78. Remler BF, Leigh J, Osorio I, Tomask RL. The characteristics and mechanisms of visual disturbance associated with anticonvulsant therapy. Neurology 1990; 40: 791-6.
79. Riker WK, Dowwnes H, Olsen GD and Smith B. Conjugate lateral gaze nystagmus and free Phenytoin concentrations in plasma: lack of correlation. Epilepsia 1978; 19: 93-8.
80. Berger JR, and Kovacs AG. Down beat nystagmus with phenytoin. J Clin Neuro Ophthalmology 1982; 2: 209-11.
81. Campbell Jr. WW. Periodic alternating nystagmus in Phenytoin intoxication. Arch Neurol 1980; 37: 178-80.
82. Spector RH, Davidoff RA, Schwartzman RJ. Phenytoin-induced ophtalmoplegia. Neurology 1976; 31: 1188-90.
83. Guiloff RJ, Whiteley A and Kelly RE. Organic convergence spasm. Acta Neurol Scand 1980; 61: 252-9.
84. Umeda Y, Sakata E. Equilibrium disorder in carbamazepine toxicity. Ann Otorhinolaryngol 1977; 86: 318-22.
85. Wheeler SD, Ramsay RE, Weiss J. Drug-induced down-beat nystagmus. Ann Neurol 1982; 12: 227-8.
86. Berchou RC. Carbamazepine-induced oculogyic crisis. Arch Neurol 1979; 36: 522-3.
87. Mullally WJ. Carbamazepine-induced ophthalmoplegia. Arch Neurol 1982; 39: 64.
88. Barret LG, Vincent FM, Arsac PL, Debru JLE, Faure JR. Internuclear ophthalmoplegia in patients with toxic coma. Frequency, prognostic value, diagnostic significance. J Toxicol Clin Toxicol 1983; 20: 373-9.
89. Simon RP. Forced downward ocular deviation. Occurrence during oculovestibular testing in sedative drug-induced coma. Arch Neurol 1978; 35: 456-8.
90. Lessell S, Wolf PA, Chronley D. Prolonged vertical nystagmus after pentobarbital sodium administration. Am J Ophthalmology 1975; 80: 151-2.
91. Edis RH, Mastaglia FL. Vertical gaze palsy in barbiturate intoxication. Br Med J 1977; 1: 144.
92. Westheimer G. Amphetamine, barbiturates, and accomodation-convergence. Arch Ophthalmol 1963; 70: 830-6.
93. O'Donnell J, Bateman DN. Lamotrigine overdose in an adult. J Toxicol Clin Toxicol 2000; 38 (6): 659-60.
94. Hwang TL, Still CN, Jones EJ. Reversible downbeat nystagmus and ataxia in Felbamate intoxication. Neurology 1995; 45: 846.
95. Bittencourt PR, Gresty MA, Richens A. Quantitative assessment of smooth-pursuit eye movements in healthy and epileptic subjects. J Neurol Neurosurg Psychiatry 1980; 43 (12): 1119-24.
96. Griffiths AN, Marshall RW, Richens A. Saccadic movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol 1984; 18: 73S-82S.
97. Gangemi PF, Messori A, Baldini S, Parigi A, Massi S, Zaccara G. Comparison of two nonlinear models for fitting saccadic eye movement data. Comp Progr Biomed 1991; 34: 291-7.
98. Zaccara G, Baldini S, Gangemi PF, Messori A, Parigi A, Nencioni C. A new method for analysing smooth-pursuit eye movements. Description of a microcomputer program and evaluation in healthy volunteers. Int J Neurol Sci 1991; 12: 537-44.
99. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with Phenytoin and diazepam. Br J clin Pharmacol 1985; 20: 619-29.
100. Tedeschi G, Casucci G, Allocca S, Riva R, Di Costanzo A, Quattrone A, Baruzzi A, Bonavita V. Computer analysis of saccadic eye movements: assessment of two different carbamazepine formulations. Eur J Clin Pharmacol 1989; 37: 513-6.
101. Zaccara G, Gangemi PF, Messori A, Parigi A, Massi S, Valenza T, Monza GC. Effects of oxcarbazepine and carbamazepine on the central nervous system: computerised analysis of saccadic and smooth-pursuit eye movements. Acta Neurol Scand 1992; 85: 425-9.
102. Hamilton MJ, Cohen AF, Yuen WC, Harkin N, Land G, Weatherley BC, Peck AW. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993; 34: 166-73.
103. Thurston SE, Leigh RJ, Abel LA, Dell'Osso LF. Slow saccades and hypometria in anticonvulsant toxicity. Neurology 1984; 34 (12): 1593-6.
104. Lempert T, Ried S, Schmidt D. Addition of vigabatrin has no effect on eye movement and posture control. In: Brandt T, Paulus W, Bles W, Dieterich M, Krafczyk S, Straube A (Eds) Disorders of posture and gait. Stuttgart, Thieme, 1990: 358-60.
105. Appleton RE, Jan JE. Efficacy of valproic acid in the treatment of Sydenham's chorea. J Child Neurol 1988; 3: 147.
106. Roig M, Montserrat L, Gallarrt A. Carbamazepine: an alternative drug for the treatment of nonhereditary chorea. Pediatrics 1988; 82: 492-5.
107. Hoffman AS, Feinberg TE. Successful treatment of age-related chorea with sodium valproate. J American Geriatrics Society 1990; 38: 56-8.
108. Harel L, Zecharia A, Straussberg R, Volovitz B, Amir J. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol 2000; 23 (2): 147-51.
109. Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham's chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain & Development 2002; 24: 73-6.
110. Sthal SM, Thornton JE, Simpson ML, Berger PA, Napoliello MJ. Gamma-Vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biol Psichiatry 1985; 20: 888-3.
111. Fisk GC, York SM. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry 1987; 150: 542-6.
112. Sayama S, Fujimoto K, Nakano I. Valproic acid relieved marked rigidity in three patients with end-stage parkinsonism. Rinsho Shinkeigaku 1998; 38: 495-8.
113. Peters HA. Anticonvulsant drug intolerance. Neurology 1962; 12: 299.
114. Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993; 8 (1): 19-27.
115. Moss W, Ojukwu C, Chiriboga CA. Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine. Clin Pediatr 1994; 33: 634-8.
116. Koukkari MW, Vanefsky MA, Steinberg GK, Hahn JS. Phenytoin-related chorea in children with deep hemispheric vascular malformations. J Child Neurol 1996; 11 (6): 490-1.
117. Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disorders 1996; 11: 111-4.
118. Chaudhary N, Ravat SH, Shah PU. Phenytoin-induced dyskinesia. Indian Pediatr 1998; 35: 274-6.
119. Montenegro MA, Scotoni AE, Cendes F. Dyskinesia induced by phenytoin. Arq Neuropsiquiatr 1999; 57: 356-60.
120. Saito Y, Oguni H, Awaya Y, Hayashi K, Osawa M. Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics 2001; 32: 231-5.
121. Girija AS. Paroxysmal dyskinesia in phenytoin toxicity. J Assoc Physicians India 2002; 50: 1449-50.
122. Opida CL, Korthals JK, Somasundaram M. Bilateral ballismus in Phenytoin intoxication. Ann Neurol 1978; 3: 186.
123. Rasmussen S, Kristensen M. Choreoathetosis during phenytoin treatment. Acta Med Scand 1977; 201 (3): 239-41.
124. Mauguiere F, Dalery J, de Villard R, Courjon J. Transient hyperkinesia after a single intravenous perfusion of diphenylhydantoin. Report of a case associated with nontoxic plasma levels of diphenylhydantoin. Eur Neurol 1979; 18: 116-23.
125. Lancman ME, Asconape JJ, Penry JK. Choreiform movements associated with the use of valproate. Arch Neurol 1994; 51: 702-4.
126. th Edition, Philadelphia, Lippincott Williams,Wilkins, 2002: 581-90.
127. Tomson T. Choreoathetosis induced by ordinary phenytoin levels, explained by high free fractions? A case report. Ther Drug Monit 1988; 19: 239-41.
128. Izumi K, Nomoto M, Koja T, Shimizu T, Kishita C, Fukuda T. Phenytoin potentiates methamphetamine-induced behavior in mice. Pharmacol Biochem Behav 1984; 20: 803-6.
129. Zaccara G, Messori A, Cincotta M. Clinical studies of pharmacodynamic interactions between antiepileptic agents and other drugs. In: Maijkowski J, Bourgeois BFD, Patsalos PN, Mattson R. (Eds) Antiepileptic drugs: combination therapy and interactions. In press.
130. Zaatreh M, Tennison M, D'Cruz O, Beach RL. Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction?. Seizure 2001; 10 (8): 596-9.
131. Joyce RP, Gunderson CH. Carbamazepine-induced orofacial dyskinesia. Neurology 1980; 30: 1333-4.
132. Schwartzman MJ, Leppik IE. Carbamazepine-induced dyskinesia and ophthalmoplegia. Cleve Clin J Med 1990; 57 (4): 367-72.
133. Bimpong-Buta K, Froescher W. Carbamazepine-induced choreoathetoid dyskinesias. J Neurol Neurosurg Psychiatry 1982; 45: 560.
134. Stryjer R, Strous RD, Bar F, Ulman AM, Rabey JM. Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen Hosp Psychiatry 2002; 24 (2): 114-5.
135. Lazarus A. Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J clin Psychopharmacol 1994; 14: 146-7.
136. Lancman ME, Asconape JJ, Penry JK. Choreiform movements associated with the use of valproate. Arch Neurol 1994; 51 (7): 702-4.
137. Gunal DI, Guleryuz M, Bingol CA. Reversible valproate-induced choreiform movements. Seizure 2002; 11 (3): 205-6.
138. Wiznitzer M, Younkin D. Phenobarbital-induced dyskinesia in a neurologically-impaired child. Neurology 1984; 34 (12): 1600-1.
139. Lightman SL. Phenobarbital dyskinesia. Postgrad Med J 1978; 54 (628): 114-5.
140. Sechi GP, Piras MR, Rosati G, Zuddas M, Ortu R, Tanca S, Agnetti V. Phenobarbital-induced buccolingual dyskinesia in oral apraxia. Eur Neurol 1988; 28 (3): 139-41.
141. Lacayo A, Mitra N. Report of a case of phenobarbital-induced dystonia. Clin Pediatr 1992; 31: 252.
142. Ehyai A, Kilroy AW, Fenichel GM. Dyskinesia and akathisia induced by ethosuximide. Am J Dis Child 1978; 132 (5): 527-8.
143. Kirschberg GJ. Dyskinesia: an unusual reaction to ethosuximide. Arch Neurol 1975; 32: 137-8.
144. Chudnow RS, Dewey RB, Lawson CR. Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch Neurol 1997; 54 (7): 910-2.
145. Reeves AL, So EL, Sharbrough FW, Krahn LE. Movement disorders associated with the use of gabapentin. Epilepsia 1996; 37 (10): 988-90.
146. Norton JW, Quarles E. Gabapentin-related dyskinesia. J Clin Psychopharmacol 2001; 21: 623-4.
147. Buetefisch CM, Gutierrez A, Gutmann L. Choreoathetotic movements: A possible side effect of gabapentin. Neurology 1996; 46 (3): 851-2.
148. Kerrick JM, Kelley BJ, Maister BH, Graves NM, Leppik IE. Involuntary movement disorders associated with felbamate. Neurology 1995; 45 (1): 185-7.
149. Wolanczyk T, Grabowska-Grzyb A. Transient dystonias in three patients treated with tiagabine. Epilepsia 2001; 42 (7): 944-6.
150. Jongsma MJ, Laan LA, van Emde Boas W, Meinardi H. Reversible motor disturbances induced by vigabatrin. Lancet 1991; 338 (8771): 893.
151. Proest G, Ried S. Acute dyskinesia in patients treated with vigabatrin. Epilepsia 1996; 37 (Suppl. 4): 72.
152. Chadwick D, Reynolds EH, Marsden CD. Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry 1976; 39 (12): 1210-8.
153. Sethi KD, Hitri A, Diamond BI. Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov Disord 1990; 5 (4): 325-7.
154. Meldrum BS. Excitatory amino acid transmitters in epilepsy. Epilepsia 1991; 32: S1-S3.
155. van der Zwan A. Transient Parkinson syndrome and tremor caused by the use of sodium valproate. Ned Tijdschr Geneeskd 1989; 17: 133: 1230-2.
156. Alvarez-Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P, Brannan T, Gudin M, Ibanez R. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451-5.
157. del Real Francia MA, Sanz Martinez J, Vaamonde Gamo J, Gudin Rodriguez-Magarinos M, Ibanez Alonso R, Rinon V. Parkinsonism induced by sodium valproate. Neurologia 1995; 10 (9): 381-3.
158. Sasso E, Delsoldato S, Negrotti A, Mancia D. Reversible valproate-induced extrapyramidal disorders. Epilepsia 1994; 35: 391-3.
159. Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 1998; 245: 794-6.
160. Park-Matsumoto YC, Tazawa T. Valproate induced parkinsonism. No To Shinkei 1998; 50: 81-4.
161. Masmoudi K, Gras-Champel V, Bonnet I, Pannier M, Masson H, Rosa A, Andrejak M. Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie 2000; 55: 629-34.
162. Barroso B. Reversible parkinsonism induced by prolonged treatment with valproate. Therapie 2002; 57: 410-1.
163. Iijima M. Valproate-induced parkinsonism in a demented elderly patient. J Clin Psychiatry 2002; 63: 75.
164. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626-35.
165. Goni M, Jimenez M, Feijoo M. Parkinsonism induced by phenytoin. Clin Neuropharmacol 1985; 8 (4): 383-4.
166. Burd L, Kerbeshian J, Fisher W, Gascon G. Anticonvulsant medications: an iatrogenic cause of tic disorders. Can J Psychiatry 1986; 31 (5): 419-23.
167. Drake ME, Cannon PA. Tourette syndrome precipitated by phenytoin. Clin Pediatr 1985; 24: 323.
168. Neglia JP, Glaze DG, Zion TE. Tics and vocalizations in children treated with carbamazepine. Pediatrics 1984; 73: 841-4.
169. Robertson PL, Garofalo EA, Silverstein FS, Komaynski MA. Carbamazepine-induced tics. Epilepsia 1993; 34: 965-8.
170. Holtmann M, Korn-Merker E, Boenigk HE. Carbamazepine-induced combined phonic and motor tic in a boy with Down's syndrome. Epileptic Disord 2000; 2 (1): 39-40.
171. Tapiador Sanjuan MJ, Zuazo Zamalloa E, Garaizar Axpe C, Prats Vinas JM. Tics and carbamazepine in benign partial epilepsy of childhood. Neurologia 1995; 10: 59-60.
172. Zawadzki Z. Carbamazepine in the treatment of the maladie des tics. Pediatr Pol 1972; 47: 1105-10.
173. Kurlan R, Kersun J, Behr J, et al.: Carbamazepine-induced tics. Clin Neuropharmacol 1989; 12 (4): 298-302.
174. Lombroso CT. Lamotrigine-induced tourettism. Neurology 1999; 52: 1191-4.
175. Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 2000; 41 (7): 862-7.
176. nd Edition, Washington DC, The American Psychiatric Press, Inc, 1998: 503-22.
177. Okada M, Hirano T, Mizuno K et al. Biphasic effects of carbamazepine on the dopaminergic system in the rat striatum and hyppocampus. Epilepsy Res 1997; 28: 143-53.
178. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-7.
179. Marciani MG, Maschio M, Spanedda F, et al. Development of myoclonus in patients with partial epilepsy during treatment with vigabatrin: an electroencephalographic study. Acta Neurol Scand 1995; 91: 1-5.
180. Aguglia U, Zappia M, Quattrone A. Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia 1987; 28: 515-8.
181. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
182. Duarte J, Sempere AP, Cabezas MC, Marcos J, Claveria LE. Postural myoclonus induced by phenytoin. Clin Neuropharmacol 1996; 19: 536-8.
183. Murphy MJ, Goldstein MN. Diphenylhydantoin-induced asterixis. A clinical study. JAMA 1974; 29; 229: 538-40.
184. Chi WM, Chua KS, Kong KH. Phenytoin-induced asterxis-uncommon or underdiagnosed? Brain Inj 2000; 14: 847-50.
185. Miralles A, Vivancos F, Ivanez V, Arpa J, Barreiro P. Acute encephalopathy with myoclonus caused by phenytoin. Apropos of a case. Rev Neurol 2001; 32: 298-99.
186. Genton P, Gelisse P. Juvenile myoclonic epilepsy. Arch Neurol 2001; 58: 1487-90.
187. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 (Suppl. 3): S2-S10.
188. Namba Y, Maegaki Y. Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Pediatr Neurol 1999; 21: 664-7.
189. Wendland KL. Myoclonus following doses of carbamazepin. Nervenartz 1968; 39: 231-3.
190. Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991; 32 (2): 275-8.
191. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia 1998; 39 (10): 1115-8.
192. Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate. Lancet 1982; 5;1 (8284): 1306.
193. Aguglia U, Gambardella A, Zappia M, Valentino P, Quattrone A. Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr Clin Neurophysiol 1995; 94 (2): 103-8.
194. Koenig SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new cases. Epilepsia 1994; 35: 1005-15.
195. Zaccara G, Paganini M, Campostrini R, Arnetoli G, Zappoli R, Moroni F. Hyperammonemia and valproate-induced alterations of the state of consciousness. Eur Neurol 1984; 23: 104-12.
196. Garcia Pastor A, Garcia-Zarza E, Peraita Adrados R. Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy. Neurologia 2000; 15 (8): 370-4.
197. Guerrini R, Travel C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998; 39: 508-12.
198. Janszky J, Rasonyi G, Halasz P, Olajos S, Perenyi J, Szucs A, Debreczeni T. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin Neuropharmacol 2000; 23 (2): 86-9.
199. Guerrini R, Belmonte A, Parmeggiani L, Perucca E. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999; 21 (6): 420-4.
200. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by Gabapentin. Neurology 1996; 46 (3): 852-3.
201. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41 (4): 479-81.
202. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42 (6): 790-2.
203. Bain PG. The management of tremor. J Neurol Neurosurg Psychiatry 2002; 72 (S1)i3-i9.
204. Louis ED. Essential tremor. N Engl J Med 2001; 345; 887-91.
205. Hyman NM, Dennis PD, Sinclair KG. Tremor due to sodium valproate. Neurology 1979; 29 (8): 1177-80.
206. th Edition, Philadelphia, Lippincott Williams,Wilkins, 2002: 837-51.
207. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Valproate tremors. Neurology 1982; 32 (4): 428-32.
208. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Treatment of valproate tremors. Neurology 1983; 33 (10): 1380-2.
209. Lancman ME, Asconape JJ, Walker F. Acetazolamide appears effective in the management of valproate-induced tremor. Mov Disord 1994; 9 (3): 369.
210. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 1993; 17; 342 (8864): 185-6.
211. Leppik IE, Gram L, Deaton R, Sommerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235-46.
212. Sasso E, Perucca E, Fava R, Calzetti S. Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord 1991; 6: 65-8.
213. Sechi GP, Zuddas M, Piredda M, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow up. Neurology 1989; 39: 1113-5.
214. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple dose, double-blind, placebo-controlled trial. Mov Disord 2000; 15: 678-82.
215. Faulkner MA, Bertoni JM, Lenz TL. Gabapentin for the treatment of tremor. Ann Pharmacother 2003; 37 (2): 282-6.
216. Galvez-Jimenez N. and Hargreave M. Topiramate and essential tremor. Ann Neurol 2000; 47: 837-8.
217. Connor GC. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002; 59: 132-4.
218. Edwards KR. Felbamate and tremor. Neurology 1995; 45(1): 185-7.
219. Benvenuti F, Bandinelli M, Mencarelli A, et al. Alterations of ballistic movements in epileptic patients with Phenytoin intoxication. Epilepsia 1992; 33 (2): 376-88.